@waywardstudios.bsky.socialWe have our winners!
Congratulations to Bryan Spellman, FamilyGames.Night, and Mike, our Road to 1500 Giveaway winners!
Thanks to everyone who helped Wayward Studios cross 1,500 followers.
And stay tuned, we’ve got another giveaway planned for closer to the end of the year.
@swisshockeynews.bsky.socialSWISS LEAGUE | Kevin Bozon practicing with HCC #HCC https://swisshockeynews.ch/en/shn/men/swiss-hockey/sl/kevin-bozon-practicing-with-hcc?utm_term=perfectpublisher&utm_campaign=social
@cddpress.bsky.social“Hepatitis B virus protein X promotes survival and loss of hepatocyte identity in a differentiated human liver organoid system”
This physiologically relevant organoid model clarifies longstanding questions about the pathogenesis of #HBV-associated #HCC ⤵️
nature.com/articles/s41...
@genesndiseases.bsky.socialWhat keeps #βCatenin active in cancer?
This study identifies #Doublecortin as a novel regulator that stabilizes β-Catenin, enhances its transcriptional activity and promotes #HCC progression. @emorydeptofmed.bsky.social
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...
@swisshockeynews.bsky.socialSWISS LEAGUE | GSHC's Jason Akeson loaned to La Chaux-de-Fonds #HCC #GSHC https://swisshockeynews.ch/en/shn/men/swiss-hockey/sl/gshcs-jason-akeson-loaned-to-la-chaux-de-fonds?utm_term=perfectpublisher&utm_campaign=social
@lancetrh-europe.bsky.socialHow can advances in #HCC care reach more patients across Europe?
The Series highlights the need for coordinated approaches across prevention, surveillance, treatment, reimbursement, and policy to reduce disparities and improve outcomes.
@lancetrh-europe.bsky.social@lancetrh-europe.bsky.socialThe landscape of hepatocellular carcinoma in Europe is changing.
Chaired by Prof David Pinato, the Series examines the evolving #HCC burden, persistent surveillance gaps, advances in treatment and inequalities in access to care.
Read more 👇
shorturl.at/qo8g1
@swisshockeynews.bsky.socialMEDICAL REPORT | HCC's Christian Pinana injured #HCC https://swisshockeynews.ch/en/shn/medical/hccs-christian-pinana-injured?utm_term=perfectpublisher&utm_campaign=social
@liversmdpi.bsky.social📢 New Review in #LiversMDPI
🧬 Jones et al. examine HCC complexity and therapeutic challenges, focusing on HuR.
🩺 Preclinical evidence supports HuR inhibition as a potential strategy in HCC.
📖 Read More: www.mdpi.com/2673-4389/6/...
@swisshockeynews.bsky.socialMEDICAL REPORT | HCC without David Eugster for months, Janik Loosli ready for comeback #HCC https://swisshockeynews.ch/en/shn/medical/hcc-without-david-eugster-for-months-janik-loosli-ready-for-comeback?utm_term=perfectpublisher&utm_campaign=social
@gpbees.bsky.social6/ 💡 Together, the study expands the landscape of potential HCC antigens beyond the canonical proteome and provides a framework for discovering and validating ncORF-derived targets for cancer immunotherapy.
@sigtrans-sttt.bsky.socialHow does #HCC withstand #OxidativeStress during therapy?
This study identifies a HIF1α–KLF4–hemoglobin axis that scavenges ROS and promotes sorafenib resistance, revealing a targetable redox adaptation.
@swisshockeynews.bsky.socialMEDICAL REPORT | HC La Chaux-de-Fonds without Janik Loosli for the time being #HCC https://swisshockeynews.ch/en/shn/medical/hc-la-chaux-de-fonds-without-janik-loosli-for-the-time-being?utm_medium=social
@northwell-journals.bsky.socialMolecular Medicine - Journal
Article in Press: Metabolism-guided precision oncology in hepatocellular carcinoma: vascular, stromal and immune crosstalk | #MolecularMedicine #HepatocelluarCarcinoma #HCC #Metabolomics link.springer.com/article/10.1...
@tickzen.bsky.socialPrice target forecast update for Warrior Met Coal, Inc. Common Stock (HCC). Horizon: 12 months. Average target: $99.61 (4.5% move). #HCC
@aasldfoundation.bsky.social💡Have a promising research idea? Apply for one of AASLD Foundation's Pilot Awards to generate new data.
Four pilot funding opportunities are now open, including the NEW Pilot Research Award in Hepatocellular Carcinoma #HCC!
📅 Apply by Dec. 7: https://bit.ly/4cnMhhD
